Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.70 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.46 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.43 |
| ▸ | CCKAR | P32238 | 4/20 | 0.42 |
| ▸ | CCKBR | P32239 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16382406 | 1.00 | GLP1R (0.70) | GLP1RFOLH1NOD1CCKARCCKBR | |
| SCHEMBL16382334 | 1.00 | GLP1R (0.70) | GLP1RFOLH1NOD1CCKARCCKBR | |
| SCHEMBL24363619 | 1.00 | GLP1R (0.70) | GLP1RFOLH1NOD1CCKARCCKBR | |
| SCHEMBL8223006 | 0.95 | GLP1R (0.67) | GLP1RFOLH1NOD1CCKARCCKBR | |
| SCHEMBL25913565 | 0.95 | GLP1R (0.67) | GLP1RFOLH1NOD1CCKARCCKBR | |
| SCHEMBL24390494 | 0.94 | GLP1R (0.66) | GLP1RFOLH1CCKARCCKBR | |
| SCHEMBL24390495 | 0.94 | GLP1R (0.66) | GLP1RFOLH1CCKARCCKBR | |
| SCHEMBL24390502 | 0.94 | GLP1R (0.66) | GLP1RFOLH1NOD1CCKARCCKBR | |
| SCHEMBL19135689 | 0.94 | GLP1R (0.69) | GLP1RFOLH1NOD1CCKARCCKBR | |
| SCHEMBL16382929 | 0.94 | GLP1R (0.62) | GLP1RFOLH1NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11779648-B2 | Co-agonists at GLP-1 and GIP receptors suitable for oral delivery | NOVO NORDISK A/S (DK) | 2023-10-10 | — | — | US | disclosed |
| US-20230120597-A1 | CO-AGONISTS AT GLP-1 AND GIP RECEPTORS SUITABLE FOR ORAL DELIVERY | NOVO NORDISK A/S (DK) | 2023-04-20 | — | — | US | disclosed |
| US-20220125940-A1 | CO-AGONISTS AT GLP-1 AND GIP RECEPTORS SUITABLE FOR ORAL DELIVERY | NOVO NORDISK A/S (DK) | 2022-04-28 | — | — | US | disclosed |
| WO-2011073328-A1 | GLP-1 RECEPTOR AGONIST COMPOUNDS WITH A MODIFIED N-TERMINUS | NOVO NORDISK A/S (DK) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220125940-A1 | CO-AGONISTS AT GLP-1 AND GIP RECEPTORS SUITABLE FOR ORAL DELIVERY | GLP1R, GIPR, GCGR | GLP1R 1/4885FOLH1 1125/4885NOD1 763/4885 |
| US-11779648-B2 | Co-agonists at GLP-1 and GIP receptors suitable for oral delivery | GLP1R, GIPR, GCGR | GLP1R 1/4885FOLH1 1125/4885NOD1 763/4885 |
| US-20230120597-A1 | CO-AGONISTS AT GLP-1 AND GIP RECEPTORS SUITABLE FOR ORAL DELIVERY | GLP1R, GIPR, GCGR | GLP1R 1/4885FOLH1 1125/4885NOD1 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.